Bavarian Nordic A/S (OTCMKTS:BVNRY) Short Interest Up 55.9% in February

Bavarian Nordic A/S (OTCMKTS:BVNRY) saw a significant growth in short interest in February. As of February 15th, there was short interest totalling 5,300 shares, a growth of 55.9% from the January 31st total of 3,400 shares. Based on an average daily volume of 24,500 shares, the short-interest ratio is currently 0.2 days.

Bavarian Nordic A/S Price Performance

Shares of BVNRY stock traded down $0.24 during trading hours on Friday, reaching $7.72. 5,561 shares of the company were exchanged, compared to its average volume of 9,633. Bavarian Nordic A/S has a fifty-two week low of $6.86 and a fifty-two week high of $14.60. The stock’s fifty day moving average is $8.60 and its two-hundred day moving average is $10.00. The company has a market cap of $1.83 billion, a price-to-earnings ratio of 11.19 and a beta of 1.68.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.